2,279 Shares of VanEck Biotech ETF $BBH Purchased by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC bought a new stake in shares of VanEck Biotech ETF (NASDAQ:BBH) during the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 2,279 shares of the company’s stock, valued at approximately $557,000.

Other institutional investors have also recently made changes to their positions in the company. Kestra Advisory Services LLC grew its position in VanEck Biotech ETF by 3.0% in the first quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock worth $640,000 after acquiring an additional 98 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in VanEck Biotech ETF by 3.4% during the first quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock worth $572,000 after acquiring an additional 100 shares during the last quarter. Coastline Trust Co bought a new stake in VanEck Biotech ETF during the third quarter worth approximately $46,000. CoreCap Advisors LLC bought a new stake in VanEck Biotech ETF during the third quarter worth approximately $46,000. Finally, Manchester Capital Management LLC purchased a new stake in VanEck Biotech ETF during the third quarter valued at approximately $74,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

Shares of BBH stock opened at $256.90 on Friday. VanEck Biotech ETF has a 1 year low of $177.35 and a 1 year high of $257.70. The stock’s 50 day simple moving average is $240.60 and its two-hundred day simple moving average is $206.44.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.